Australia markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
147.52-1.27 (-0.85%)
At close: 04:00PM EDT
147.51 -0.01 (-0.01%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close148.79
Bid147.47 x 800
Ask147.70 x 800
Day's range147.15 - 149.07
52-week range144.95 - 175.97
Avg. volume7,193,125
Market cap355.491B
Beta (5Y monthly)0.53
PE ratio (TTM)28.42
Earnings dateN/A
Forward dividend & yield4.76 (3.23%)
Ex-dividend date16 Feb 2024
1y target estN/A
  • PR Newswire

    CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

    Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy

  • Business Wire

    Johnson & Johnson to Acquire Shockwave Medical

    NEW BRUNSWICK, N.J. & SANTA CLARA, Calif., April 05, 2024--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies’ boards of directors.

  • Business Wire

    Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation

    NEW BRUNSWICK, N.J., April 04, 2024--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash. TRC Capital Investment’s offer price of $151.23 per share is approximately 4.12% lower than the $157.73 closing share price of Johnson & Johnson’s common stock on April 2, 2024, the busi